RenovoRx (RNXT) announced continuing momentum with the company’s RenovoCath commercial strategy, with new purchase orders received from several esteemed, high volume National Cancer Institute-designated centers. Additionally, RenovoRx reported that utilization of RenovoCath devices by its initial customers announced this past December has led to repeat purchase orders. Together, these announcements demonstrate that RenovoRx is continuing on the path to initial revenue generation from RenovoCath sales this quarter and that revenues could begin to ramp during the course of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
Questions or Comments about the article? Write to editor@tipranks.com